In support of this theory, Pender et al. recently performed a trial where they treated a patient with secondary progressive MS using AdE-1-LMPpoly, a recombinant adenovirus vector that encodes multiple CD8+ T-cell epitopes from the latent EBV proteins EBNA1, LMP1, and LMP2A (38). Here, CD8A is linked to myeloid sarcoma.